Feature | October 31, 2013

Boston Scientific Receives CE Mark for Lotus Valve System

TAVR device offers precise positioning and placement, offering physicians unprecedented control

heart valve repair hybrid or cath lab
October 31, 2013 — Boston Scientific Corp. has received CE mark for its Lotus Valve System, a transcatheter aortic valve replacement (TAVR) technology. This key approval offers an effective new treatment alternative for patients with severe aortic stenosis at high risk with surgical valve replacement.
 
The Lotus Valve System is immediately available to select centers in Europe, with commercial site expansion accelerating as physicians and centers become fully trained. It is designed to provide physicians increased control during implantation and to help provide a more precise, predictable procedure. It is the only aortic valve device that can be assessed in its final position prior to release while maintaining the ability for the physician to reposition or fully resheath and retrieve the valve. The Lotus Valve System also incorporates Adaptive Seal technology designed to minimize aortic regurgitation.
 
"The ability to initially position the Lotus Valve precisely and, if needed, to easily reposition or fully retrieve the valve provides the operator with remarkable control," said Ian Meredith, director of MonashHeart at Monash Medical Centre, Melbourne, Australia and principal investigator, REPRISE II trial. "Combined with early and often complete elimination of aortic regurgitation as observed in REPRISE II, the unique features of the Lotus Valve technology represent a significant step forward in the percutaneous treatment of eligible patients with severe symptomatic aortic stenosis."
 
Data presented at the PCR London Valves course in September demonstrated the Lotus Valve System met the primary performance endpoint for the first 60-patient cohort and was implanted successfully in all patients with no cases of severe paravalvular regurgitation. In 76.1 percent of patients, there was no corelab adjudicated paravalvular regurgitation at six months.
 
"Results from the REPRISE II trial highlight the promise behind the Lotus Valve System, especially related to avoiding moderate or severe paravalvular leaks," said Nicolas Van Mieghem, M.D., Erasmus Medical Center, Rotterdam, Netherlands. "In addition to providing a new treatment option for TAVR, the Lotus Valve has the potential to improve clinical outcomes by minimizing paravalvular leaks."
 
The Lotus Valve System comes pre-loaded on a transfemoral delivery system, which is inserted through a small incision in the leg. Available in a 23 mm and 27 mm size, the Lotus Valve System can treat patients with aortic annulus sizes from 20 mm to 27 mm. The Lotus Valve System is an investigational device in the United States and Japan, and is not available for sale in those countries.
 
For more information: www.bostonscientific.com

Related Content

TAVR, medical guidelines, ACC/AHA, optimization, transcatheter aortic valve replacement
News | Heart Valve Technology| January 18, 2017
The American College of Cardiology recently released new guidance for clinicians and hospitals to use in assessing...
Medtronic, CoreValve Evolut R 34 mm valve, TAVI, CE Mark, European launch
News | Heart Valve Technology| January 17, 2017
Medtronic plc announced the CE (Conformité Européenne) mark and European launch of the CoreValve Evolut R 34 mm valve...
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
Medtronic, CoreValve Evolut R TAVR system, U.S. IDE Study, TCT 2016
News | Heart Valve Technology| November 03, 2016
Medtronic plc unveiled new clinical data showing that patients treated with the self-expanding CoreValve Evolut R...
congenital heart patients, cardiac cath lab, anesthesia sedation practices, joint document, SCAI, SPA, CCAS
News | Congenital Heart| November 03, 2016
The Society for Cardiovascular Angiography and Interventions (SCAI), the Society for Pediatric Anesthesia (SPA) and the...
open-heart surgery, PCI, percutaneous coronary intervention, NOBLE trial, left main coronary artery disease, LMCAD, TCT 2016
News | Cardiovascular Surgery| November 03, 2016
Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main...
SENTINEL trial, transcatheter embolic protection, TCEP, TAVR, stroke, TCT 2016
News | Embolic Protection Devices| November 03, 2016
An international study has found that transcatheter cerebral embolic protection (TCEP) is safe, provides effective...
News | Drug-Eluting Balloons| November 03, 2016
The Spectranetics Corp. announced that it has submitted to the U.S. Food & Drug Administration (FDA) its Pre-Market...
RESPECT trial, Amplatzer PFO Occluder, St. Jude Medical, TCT 2016
News | Structural Heart Occluders| November 02, 2016
St. Jude Medical Inc. announced the long-term data from RESPECT, a landmark trial, during a First Report session at the...
Medtronic, Resolute Integrity DES, drug-eluting stent, BIO-RESORT study, TCT 2016
News | Stents Drug Eluting| November 02, 2016
Investigators recently unveiled clinical data from the independent BIO-RESORT study, representing the first all-comers...
Overlay Init